ACS Appl Mater Interfaces

1. METWALLY S, Gil D, Smialek-Bartyzel J, Pabijan J, et al
   Matrix Mechanics Governs Mechano-Metabolic Adaptation across Cancer Grades in Bladder Spheroids.
   ACS Appl Mater Interfaces. 2026;18:30775-30789.
   

   >> Share

   
   

   
   ACS Omega

2. DA ANUNCIACAO KF, Roquete Amparo T, Dutra Sousa LR, Xavier VF, et al
   Mucoadhesive Nanoemulsion Enhances the Antineoplastic Potential of Naringenin in Bladder Cancer Cell Lines.
   ACS Omega. 2026;11:30606-30616.
   

   >> Share

   
   

   
   Actas Urol Esp (Engl Ed)

3. AYTEN A, Ceylan H, Kinik AH, Gelmis M, et al
   Is the Modified Frailty Index-5 a reliable predictor of postoperative morbidity in elderly radical cystectomy patients? A comparative study with CCI and G8.
   Actas Urol Esp (Engl Ed). 2026;50:501902.
   

   >> Share

   
   
4. GOMEZ DEL CANIZO C, Fernandez Sanchez N, Gonzalez Ginel I, Hernandez Arroyo M, et al
   The use of presurgical urine cytology improves patient selection for a single instillation of MMC.
   Actas Urol Esp (Engl Ed). 2026;50:501904.
   

   >> Share

   
   
5. MARTINEZ RODRIGUEZ P, Poza Fernandez A, Garcia Fadrique G, Acedo Gonzalez J, et al
   Bladder and rectal cancer development in prostate cancer patients treated with surgery or radiotherapy: A population-based study.
   Actas Urol Esp (Engl Ed). 2026;50:501928.
   

   >> Share

   
   

   
   Adv Sci (Weinh)

6. HUANG S, Zhou Z, Xie Q, Wang Z, et al
   KRT14 Drives Basal Muscle-Invasive Bladder Cancer Progression and Lung Metastasis by Directly Binding to and Stabilizing IGF2BP1.
   Adv Sci (Weinh). 2026 Jun 9:e75900. doi: 10.1002/advs.75900.
   

   >> Share

   
   

   
   Aktuelle Urol

7. EICHENAUER R, Johannsen M, Klier J, Konig F, et al
   [Current Data from the National Registry for Urothelial Cancer (UroNAT) by d-uo].
   Aktuelle Urol. 2026;57:266-269.
   

   >> Share

   
   

   
   Arch Esp Urol

8. LIU F, Hu X, Zhu X, Han T, et al
   A Retrospective Follow-up Study on the Effects of Different Intravesical Treatments on Recurrence Control and Quality of Life in Patients With Non-Muscle-Invasive Bladder Cancer After Transurethral Resection of Bladder Tumour.
   Arch Esp Urol. 2026;79:632-640.
   

   >> Share

   
   

   
   Arch Razi Inst

9. PALAGAN SENOPATI S, Willy Moris N, I Made K, Ida Bagus Oka W, et al
   A Case of Urothelial Carcinoma in Situ of the Bladder in Local Dog in Bali, Indonesia.
   Arch Razi Inst. 2025;80:1345-1352.
   

   >> Share

   
   

   
   Biomed Res Int

10. RESEARCH INTERNATIONAL B
    RETRACTION: Omega-3 Fatty Acids Inhibit Tumor Growth in a Rat Model of Bladder Cancer.
    Biomed Res Int. 2026;2026:e9864535.
    

    >> Share

    
    

    
    BJU Int

11. VAN HATTUM JW, Remmelink MJ, Oddens JR, de Reijke TM, et al
    Response letter 'A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer'.
    BJU Int. 2026 Jun 9. doi: 10.1111/bju.70295.
    

    >> Share

    
    
12. UROLAGIN D, Sowmya BA, Kavyashree MV
    Comment on 'A study of oral metformin for the intravesical treatment of non-muscle-invasive bladder cancer'.
    BJU Int. 2026 Jun 10. doi: 10.1111/bju.70296.
    

    >> Share

    
    
13. NOLAZCO JI, Melnick KR, Lee RJ, Efstathiou JA, et al
    Alternatives to radical cystectomy: a bladder-sparing approach in appropriately selected patients.
    BJU Int. 2026;138:22-32.
    

    >> Share

    
    
14. ORECCHIA L, Gerardi M, Colalillo G, Leonardis F, et al
    Impact of audit and feedback on transurethral resection of bladder tumour quality: a monocentric post-completion evaluation of the RESECT trial.
    BJU Int. 2026;138:92-99.
    

    >> Share

    
    

    
    BJUI Compass

15. MALIK T, Denfhy J, Theinkha Lin H, Mohammed L, et al
    Multicentre real-world evaluation of the Haematuria Cancer Risk Score to risk-stratify the detection of bladder cancer in patients referred from primary care.
    BJUI Compass. 2026;7:e70233.
    

    >> Share

    
    

    
    BMC Urol

16. ALASKER A, Alghafees M, Nammor T, Alanazi N, et al
    Immunotherapy in bladder cancer: a systematic review of clinical trials and therapeutic advances.
    BMC Urol. 2026 Jun 8. doi: 10.1186/s12894-026-02209.
    

    >> Share

    
    

    
    BMJ Open

17. KAGENAAR E, Lugo-Palacios DG, Bromley H, Aggarwal A, et al
    Surgery or radiotherapy for early-stage cancer study protocol for an emulated target trial of radical radiotherapy versus radical cystectomy, with either following neoadjuvant chemotherapy, for organ-confined muscle-invasive bladder cancer.
    BMJ Open. 2026;16:e119596.
    

    >> Share

    
    

    
    Cancer

18. MEHTA S, Weinfeld M, Hobeika C, Reizine N, et al
    The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration.
    Cancer. 2026;132:e70448.
    

    >> Share

    
    

    
    Cancer Cell Int

19. ZHAO H, Li K, Xu H, Liao J, et al
    Multi-dimensional profiling of lactylation-related signatures for prognostic and therapeutic insights in bladder cancer.
    Cancer Cell Int. 2026 Jun 6. doi: 10.1186/s12935-026-04364.
    

    >> Share

    
    

    
    Cancer Imaging

20. CHEN C, Tan Z, Cai L, Chen H, et al
    MRI-based deep learning combined with radiomics for the preoperative prediction of lymphovascular invasion in patients with bladder cancer.
    Cancer Imaging. 2026 Jun 11. doi: 10.1186/s40644-026-01070.
    

    >> Share

    
    

    
    Cancer Nurs

21. DENG C, Soivong P, Akkadechanunt T, Sethabouppha H, et al
    Self-Management Experience of Chinese Patients With Nonmuscle-Invasive Bladder Cancer During Intravesical Therapy: A Qualitative Study.
    Cancer Nurs. 2026 May 28. doi: 10.1097/NCC.0000000000001598.
    

    >> Share

    
    

    
    Cancer Sci

22. ZENG Y, Gu G, Yang L, Fan B, et al
    Ketogenic Diet and beta-Hydroxybutyrate Suppress Bladder Cancer Growth and Enhance Anti-PD-L1 Immunotherapy Efficacy.
    Cancer Sci. 2026 Jun 11. doi: 10.1111/cas.70447.
    

    >> Share

    
    

    
    Cancers (Basel)

23. ZHU J, Wang A, Tong H, Sun Y, et al
    Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway.
    Cancers (Basel). 2026;18:1713.
    

    >> Share

    
    
24. SHAH KU, Castro DV, Li X, Zugman M, et al
    Evaluating Worldwide Disparities in Bladder Cancer Clinical Trial Availability.
    Cancers (Basel). 2026;18:1730.
    

    >> Share

    
    
25. HJORT PB, Skovhus K, Jensen JB, Ernst A, et al
    Study of Bladder Cancer Detection in Standard White Light Versus AI-Supported Endoscopy-02 (RAISE-02)-A Randomized Controlled Non-Inferiority Trial.
    Cancers (Basel). 2026;18:1739.
    

    >> Share

    
    
26. CERIA F, Muhammad G, Del Giudice F, Ibrahim Y, et al
    Expect the Unexpected: Frequency, Predictors, and Survival Impact of Pathological Upstaging from Non-Muscle-Invasive to Muscle-Invasive Bladder Cancer Following Radical Cystectomy.
    Cancers (Basel). 2026;18:1733.
    

    >> Share

    
    

    
    Cell Death Dis

27. YAN D, Zhu W, Tao Y, Huang L, et al
    ZRANB1 promotes cell proliferation and lymph node metastasis through SF3B3-mediated alternative splicing of CHEK2 in urothelial bladder cancer.
    Cell Death Dis. 2026 Jun 9. doi: 10.1038/s41419-026-08964.
    

    >> Share

    
    

    
    Cell Oncol (Dordr)

28. PENG J, Zhu Q, Li S, Xiang B, et al
    Cis-3-hexen-1-ol suppresses bladder cancer progression by inducing mitophagy via the PCK2/AMPK/mTOR signaling pathway.
    Cell Oncol (Dordr). 2026 Jun 8. doi: 10.1007/s13402-026-01233.
    

    >> Share

    
    

    
    Clin Nucl Med

29. ZHANG B, Li S, Lv C, Wang W, et al
    True Positive 18F-FDG PET/CT and Negative 123I-MIBG SPECT/CT in a Pediatric Patient With Bladder Malignant Paraganglioma.
    Clin Nucl Med. 2026 Mar 31. doi: 10.1097/RLU.0000000000006377.
    

    >> Share

    
    
30. MAN X, Dong C, Dong A, Song X, et al
    FDG PET/CT in a Case of Inflammatory Myofibroblastic Tumor of the Bladder.
    Clin Nucl Med. 2026 Feb 13. doi: 10.1097/RLU.0000000000006381.
    

    >> Share

    
    
31. ZHENG K, Liu Y, Wang Y, Jing H, et al
    An Asymptomatic Urachal Mucinous Adenocarcinoma on FDG PET/CT.
    Clin Nucl Med. 2026 Mar 25. doi: 10.1097/RLU.0000000000006357.
    

    >> Share

    
    

    
    Cochrane Database Syst Rev

32. MAISCH P, Hamidi Madani M, Koziarz A, Narayan VM, et al
    Blue versus white light for transurethral resection of non-muscle invasive bladder cancer.
    Cochrane Database Syst Rev. 2026;6:CD013776.
    

    >> Share

    
    

    
    Comb Chem High Throughput Screen

33. LYU G, Li D
    Unraveling the Role of miR-33a-5p in Bladder Cancer Progression: Clinical Significance and Functional Pathways.
    Comb Chem High Throughput Screen. 2026.
    

    >> Share

    
    

    
    Curr Opin Urol

34. NEUENSCHWANDER A, Uleri A, Grobet-Jeandin E, Contieri R, et al
    Impact of a multidisciplinary approach on outcomes in urothelial carcinoma.
    Curr Opin Urol. 2026;36:446-452.
    

    >> Share

    
    

    
    Dermatol Online J

35. JOHNSON M, Clark M, Whittington C, Newton E, et al
    Adverse dermatologic effects of erdafitinib in a patient with metastatic urothelial carcinoma.
    Dermatol Online J. 2026;32.
    

    >> Share

    
    

    
    Diagnostics (Basel)

36. YAP M, Mihai IM, Alanazi MAA, Olteanu GE, et al
    Automated H-Scoring in Muscle-Invasive Bladder Cancer IHC: An Internal Validation Study.
    Diagnostics (Basel). 2026;16:1673.
    

    >> Share

    
    

    
    Discov Oncol

37. FENG W, He W
    Integrative multi-omics identifies a glycosylation-based prognostic framework and nominates ALG3 for targeted therapy in bladder cancer.
    Discov Oncol. 2026 Jun 7. doi: 10.1007/s12672-026-05387.
    

    >> Share

    
    

    
    Ecotoxicol Environ Saf

38. KAN H, Chen M, Hu W, Yang N, et al
    Exploring a critical time window for FOXM1-driven bladder injury in chronic arsenic exposure.
    Ecotoxicol Environ Saf. 2026;319:120312.
    

    >> Share

    
    

    
    Eur J Clin Pharmacol

39. LIAO J, Li X, Li G
    Comparative efficacy and safety of carboplatin-based versus cisplatin-based chemotherapy in muscle-invasive and advanced bladder cancer: A systematic review and meta-analysis.
    Eur J Clin Pharmacol. 2026;82:168.
    

    >> Share

    
    

    
    Eur Urol Oncol

40. SIVA J, Jonnalagadda R, Aydogdu C, Diaz GM, et al
    External Validation of the International Bladder Cancer Group Intermediate-risk Non-muscle-invasive Bladder Cancer Substratification Model.
    Eur Urol Oncol. 2026 Jun 11:S2588-9311(26)00157.
    

    >> Share

    
    

    
    Front Oncol

41. PAN Y, Sun Y, Jiao B, Zhang Y, et al
    The international and domestic research trends of targeted therapy in bladder cancer: a bibliometric analysis of the past three decades.
    Front Oncol. 2026;16:1850175.
    

    >> Share

    
    

    
    Hinyokika Kiyo

42. SAKAI T, Abe T, Mizuno R, Izumi H, et al
    [LYMPH NODE TUBERCULOSIS AFTER INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR BLADDER CARCINOMA IN SITU : A CASE REPORT].
    Hinyokika Kiyo. 2026;72:171-176.
    

    >> Share

    
    

    
    Int J Mol Sci

43. ANTONOV P, Raycheva G, Eshrefov D, Belov A, et al
    FGFR3 Alterations and Nectin-4 Expression as Therapeutic Biomarkers in Bladder Cancer: A Systematic Review and Single-Arm Meta-Analysis.
    Int J Mol Sci. 2026;27:5007.
    

    >> Share

    
    

    
    Int J Urol

44. ENDO Y, Sakura Y, Kaneko G, Hayakawa N, et al
    Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real-World Multicenter Study.
    Int J Urol. 2026;33:e70523.
    

    >> Share

    
    
45. KOBAYASHI G, Sekino Y, Miyamoto S, Kobatake K, et al
    Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset.
    Int J Urol. 2026;33:e70538.
    

    >> Share

    
    

    
    Int Urol Nephrol

46. MCMASTER T, Hoskin G, Homewood D, Attwell-Heap A, et al
    A comparative analysis of variant histology and urothelial bladder cancer following radical cystectomy.
    Int Urol Nephrol. 2026 Jun 10. doi: 10.1007/s11255-026-05234.
    

    >> Share

    
    

    
    J Clin Med

47. DEGIRMENCI E, Sanli O, Kaytaz M, Kucukgergin C, et al
    ZEB1-AS1 and miR-200b-3p Expression in Non-Muscle-Invasive Bladder Cancer: Pathological Correlates.
    J Clin Med. 2026;15:4182.
    

    >> Share

    
    
48. SKOVHUS K, Kristensen P, Sindberg DB, Orum M, et al
    Preoperative Frailty Assessed by the Record-Based Multidimensional Prognostic Index Predicts 90-Day Days Alive and out of Hospital Following Radical Cystectomy for Bladder Cancer: A Retrospective Cohort Study.
    J Clin Med. 2026;15:4057.
    

    >> Share

    
    

    
    J Exp Clin Cancer Res

49. HU D, Shen C, Liu C, Xie F, et al
    NOTCH3 regulates myofibroblastic CAF differentiation via the P62-ROS signaling axis to promote bladder cancer progression.
    J Exp Clin Cancer Res. 2026 Jun 6. doi: 10.1186/s13046-026-03751.
    

    >> Share

    
    

    
    J Natl Med Assoc

50. FREDERIC J, Oladoyin V, Geetha J, Muhammad A, et al
    Primary Enteric-type adenocarcinoma of the bladder managed with colon-type chemotherapy: A rare case and literature review.
    J Natl Med Assoc. 2026;118:442-445.
    

    >> Share

    
    

    
    J Pathol

51. SU X, Duan X, Bai S, Su P, et al
    Cellular origins and etiological factors for squamous cell carcinoma and related cancer types of the bladder.
    J Pathol. 2026;269:297-313.
    

    >> Share

    
    

    
    J Pharm Biomed Anal

52. SYED P, Islam MK, Kekki H, Terava J, et al
    Glycovariant-based diagnosis of bladder cancer using urinary mucin 1 and carcinoembryonic antigen.
    J Pharm Biomed Anal. 2026;280:117589.
    

    >> Share

    
    

    
    J Proteomics

53. IDIARTE JF, Canclini L, Alem D, Garcia-Lavina CX, et al
    Violacein as a multitarget agent in bladder cancer cells.
    J Proteomics. 2026 Jun 11:105697. doi: 10.1016/j.jprot.2026.105697.
    

    >> Share

    
    

    
    J Surg Case Rep

54. LEFRANC R, Mathieu C, Ghorbel A, Leger-Vigot A, et al
    Consolidative cystectomy after complete response to enfortumab vedotin plus pembrolizumab in metastatic bladder cancer: a case report.
    J Surg Case Rep. 2026;2026:rjag435.
    

    >> Share

    
    

    
    Jpn J Clin Oncol

55. SUGAHARA D, Murofushi KN, Yamashita H, Ogo E, et al
    Real-world outcomes of definitive chemoradiotherapy for bladder cancer: a multi-institutional retrospective study in Japan.
    Jpn J Clin Oncol. 2026 Jun 5:hyag063. doi: 10.1093.
    

    >> Share

    
    

    
    medRxiv

56. ERNANDEZ J, Xiang L, Adler R, Hsu J, et al
    Dementia and Frailty Impact Postoperative Care Trajectories and Burden among Older Adults Undergoing Radical Cystectomy for Bladder Cancer.
    medRxiv [Preprint]. 2026 Jun 6:2026.06.04.26354768.
    

    >> Share

    
    

    
    Nat Nanotechnol

57. DU R, Yu Z, Liu D
    Nanosensor-coated catheters for bladder cancer detection.
    Nat Nanotechnol. 2026 Jun 5. doi: 10.1038/s41565-026-02173.
    

    >> Share

    
    

    
    Onco Targets Ther

58. 
    Nodal Regulates Bladder Cancer Cell Migration and Invasion via the ALK/Smad Signaling Pathway [Retraction].
    Onco Targets Ther. 2026;19:629839.
    

    >> Share

    
    

    
    Oncol Ther

59. MUSONE M, Barone B, Chianese S, Conforti P, et al
    Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer.
    Oncol Ther. 2026 Jun 11. doi: 10.1007/s40487-026-00445.
    

    >> Share

    
    
60. SQUIRES P, Meng K, Hu X, Turzhitsky V, et al
    Publisher Correction: Perioperative Treatment Patterns for Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Adjuvant Immunotherapy Era: A Retrospective Analysis of US Community Oncology Practice.
    Oncol Ther. 2026 Jun 9. doi: 10.1007/s40487-026-00451.
    

    >> Share

    
    

    
    Pak J Med Sci

61. NUSRAT NB, Imtiaz S, Aslam A, Rehman AU, et al
    Clinical and pathological factors associated with recurrence after radical cystectomy for bladder cancer: A single-center retrospective study.
    Pak J Med Sci. 2026;42:932-937.
    

    >> Share

    
    

    
    PLoS One

62. CHEN X, Wang Z, Rong Y, Zhu Z, et al
    Elevated ICAM5 as a promising predictor of poor prognosis in bladder cancer via EMT, immune microenvironment, and therapy resistance.
    PLoS One. 2026;21:e0347623.
    

    >> Share

    
    
63. ZHANG Q, He C, Hong Y, Huang T, et al
    EP300 promotes bladder cancer cell migration through SNAI2.
    PLoS One. 2026;21:e0347209.
    

    >> Share

    
    

    
    Technol Cancer Res Treat

64. HE Y, Xie W, Chen W, Dai S, et al
    Urine IRF4/PENK/PXDN Methylation Signatures Enable Machine Learning-Driven Bladder Cancer Detection and Microenvironment Dissection.
    Technol Cancer Res Treat. 2026;25:15330338261453486.
    

    >> Share

    
    

    
    Urol J

65. BENLIOGLU C, Kalyenci B, Yucel MO, Cift A, et al
    A Intravesical Brucella Abortus S19 (BAS19) Vaccine As A Potential Alternative To Bacillus Calmette-Guerin (BCG) Immunotherapy: A Preclinical Study In Rats.
    Urol J. 2026;23:12-20.
    

    >> Share

    
    

    
    Urol Oncol

66. WHITE RE, Linscott JA, Pelletier C, Santos E, et al
    Optimizing radical cystectomy recovery: The role of modified ERAS in improving postoperative outcomes.
    Urol Oncol. 2026;44:316-322.
    

    >> Share

    
    
67. YAJIMA S, Yoshida S, Chen W, Fukushima H, et al
    Mixture cure model analysis of event-free survival in the NIAGARA Trial: Quantifying the cure fraction benefit of perioperative durvalumab in muscle-invasive bladder cancer.
    Urol Oncol. 2026;44:120-126.
    

    >> Share

    
    
68. PETIX M, Polverino F, Quarta L, Filzmayer M, et al
    Effect of marital status on years of life lost from metastatic bladder cancer according to sex and race/ethnicity.
    Urol Oncol. 2026;44:132-137.
    

    >> Share

    
    

    
    Urology

69. EFENDIOGLU F, Ozcan C, Turkmen V, Ugurlu O, et al
    Effect of Catheter Type and Size on Patient Comfort and Complications in Intravesical Bacillus Calmette-Guerin and Chemotherapy Administration: A Randomized Prospective Pilot Study.
    Urology. 2026;212:51-56.
    

    >> Share

    
    
70. NATHAN KK, Duke Herrell S, Westerman MB, Bjurlin MA, et al
    From Lichtleiter to Laser: A 200-Year Odyssey of Transurethral Resection of Bladder Tumors.
    Urology. 2026;212:116-121.
    

    >> Share

    
    

    
    Wien Med Wochenschr

71. PADICKAKUDY R, Rosa de Pauli L
    [Reconstructive aspects of radical cystectomy with orthotopic bladder replacement].
    Wien Med Wochenschr. 2026;176.
    

    >> Share

    
    

    
    World J Urol

72. MANGOLD MH, Egen L, Carl N, Renner LV, et al
    Radical cystectomy in octogenarians: a propensity score-matched analysis of short-term outcomes.
    World J Urol. 2026;44:405.
    

    >> Share

    
    
73. TOUMA SAWAYA R, Nasrallah O, El Hajj A, Abdessater M, et al
    Impact of CKD on perioperative outcomes following TURBT: a national NSQIP analysis.
    World J Urol. 2026;44:411.
    

    >> Share

    
    
74. SANTARELLI V, Asero V, Corvino R, De Berardinis E, et al
    Nephroureterectomy for upper tract urothelial carcinoma recurrence in bladder cancer patients treated with radical cystectomy: a multicentric propensity score matched analysis on predictors, practice patterns and survival outcomes.
    World J Urol. 2026;44:419.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share